The 2024 ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Management advise against the cessation of anti-TNF agents, vedolizumab, and Ustekinumab, and that, as such, they should be continued until surgery [14]. This evidence concerns the gene TNF and Crohn disease.